U.S. markets closed

LogicBio Therapeutics, Inc. (LOGC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.49-0.10 (-1.16%)
At close: 4:00PM EST

8.49 0.00 (0.00%)
After hours: 4:00PM EST

Full screen
Loading interactive chart...
  • LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute
    PR Newswire

    LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute

    LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the expansion of the Company's research partnership with Children's Medical Research Institute (CMRI) to develop next-generation adeno-associated virus (AAV) vectors for a range of gene therapy and gene editing applications in the treatment of serious diseases of the liver and two other tissues.

  • LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
    PR Newswire

    LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

    LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET. Mr. Chereau will provide an overview of company operations including development of its proprietary genome editing platform GeneRide and its next-generation synthetic capsids. He will also participate in one-on-one sessions with investors during the virtual conference.

  • Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer
    PR Newswire

    Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer

    LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the Company's chief financial officer, effective January 11, 2021. Matthias Jaffe, the current CFO at LogicBio, will step down at the end of the year and will remain a consultant to the Company during 2021.